Creation of an adequate animal model of hyperuricemia (acute and chronic hyperuricemia); study of its reversibility and its maintenance.


Journal

Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521

Informations de publication

Date de publication:
01 Mar 2021
Historique:
received: 21 09 2020
revised: 18 12 2020
accepted: 27 12 2020
pubmed: 9 1 2021
medline: 6 3 2021
entrez: 8 1 2021
Statut: ppublish

Résumé

Hyperuricemia is defined by the European Rheumatology Society as a uric acid level greater than 6 mg/dl (60 mg/l or 360 μmol/l). Our goal was to evaluate the hypouricemic effect of nettle. For this reason, we have first of all try to create an hyperuricemic animal model which is very suitable because at the level of literature there is not an exact model, there are many models and our objective is to set an adequate model. An attempt has been made to test acute and chronic hyperuricemia by varying the duration and method of induction of potassium oxonate. Similarly, attempts have been made to induce chronic hyperuricemia through an animal and vegetable diet. The reversibility of hyperuricemia was tested with a maintenance protocol. For the creation of the hyperuricemia model, it has been shown that acute hyperuricemia cannot be induced by short administration of potassium oxonate and persistent chronic hyperuricemia can be induced only after daily administration of oxonate of potassium by intraperitoneal injection for 15 days. Indeed, hyperuricemia was reversible after stopping the administration of potassium oxonate. The high-purine diet is also capable of inducing chronic hyperuricemia but to a less extent. After creating an adequate model of hyperuricemia while setting the dose of potassium oxonate, route of administration and duration. A maintenance protocol was followed which subsequently made it possible to deduce that the daily administration of potassium oxonate must be continued to maintain the hyperuricemia.

Identifiants

pubmed: 33417953
pii: S0024-3205(20)31758-6
doi: 10.1016/j.lfs.2020.118998
pii:
doi:

Substances chimiques

Antioxidants 0
Biomarkers 0
Uric Acid 268B43MJ25
potassium oxonate 4R7FFA00RX
Oxonic Acid 5VT6420TIG
Urea 8W8T17847W
Creatinine AYI8EX34EU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118998

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Raouia Dhouibi (R)

Laboratory of Pharmacology, Faculty of Medicine of Sfax, University of Sfax, Tunisia. Electronic address: dhouibi.raouia@yahoo.com.

Hanen Affes (H)

Laboratory of Pharmacology, Faculty of Medicine of Sfax, University of Sfax, Tunisia. Electronic address: affeshanen13@yahoo.fr.

Maryem Ben Salem (MB)

Laboratory of Pharmacology, Faculty of Medicine of Sfax, University of Sfax, Tunisia.

Dorsaf Moalla (D)

Laboratory of Pharmacology, Faculty of Medicine of Sfax, University of Sfax, Tunisia.

Rim Marekchi (R)

Laboratory of Biochemistry, CHU Hedi Cheker of Sfax, Tunisia.

Slim Charfi (S)

Department of Anatomopathology, CHU Habib Bourguiba of Sfax, Tunisia.

Serria Hammami (S)

Laboratory of Pharmacology, Faculty of Medicine of Sfax, University of Sfax, Tunisia.

Zouheir Sahnoun (Z)

Laboratory of Pharmacology, Faculty of Medicine of Sfax, University of Sfax, Tunisia.

Kamel Jamoussi (K)

Laboratory of Biochemistry, CHU Hedi Cheker of Sfax, Tunisia.

Khaled Mounir Zeghal (KM)

Laboratory of Pharmacology, Faculty of Medicine of Sfax, University of Sfax, Tunisia.

Kamilia Ksouda (K)

Laboratory of Pharmacology, Faculty of Medicine of Sfax, University of Sfax, Tunisia.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH